4CPS-264 Population pharmacokinetic model of etanercept in rheumatic disease: prognostic factors and dose recommendations

BACKGROUND: Etanercept is an approved monoclonal antibody for the treatment of rheumatic disease (RD). Individual clinical response to etanercept can be influenced by their pharmacokinetics (PK) and immunogenicity, so therapeutic drug monitoring (TDM) can guide these biologic treatments. PURPOSE: De...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Eur J Hosp Pharm
Auteurs principaux: Sanchez-Hernandez, JG, Pérez-Blanco, JS, Beunza-Sola, M, Rebollo-Diaz, N, Saez-Fernandez, EM, Laso-Lucas, E, Rodriguez-Cajaraville, L, Calvo, MV
Format: Artigo
Langue:Inglês
Publié: BMJ Group 2018
Sujets:
Section 4: Clinical pharmacy services
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535412/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.354
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires